Recent advances and emerging therapeutic strategies for HFrEF include the use of angiotensin receptor-neprilysin inhibitors (ARNIs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in addition to evidence-based medications such as beta-blockers and mineralocorticoid receptor antagonists (MRAs), considered the ‘four pillars’ of heart failure treatment. The gene discussed is SLC5A2; the disease is heart failure.